Netilmicin
Active ingredient · 2 therapeutic classes
Sold as NETILDEX
- Drug class
- Other Aminoglycosides
- Availability
- See label
- Routes
- Ophthalmic
- Markets covered
- 2
- Products on record
- 7
Overview
Netilmicin is an active pharmaceutical ingredient in the Other Aminoglycosides group (J01GB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | January 16, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
GBUnited Kingdom· MHRA
5 products
Uses
Nettacin is indicated for the topical treatment of external infections of the eye and its adnexa caused by netilmicin sensitive bacteria. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
2 products
Uses
PrNETILDEX® (netilmicin and dexamethasone ophthalmic solution) is indicated in adult patients (including the elderly) for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NETILDEX and other antibacterial drugs, NETILDEX should be used only to reduce the risk of infections that are proven or strongly suspected to be caused by susceptible bacteria.
1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (>65 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
Drug interactions
Known interactions involving Netilmicin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB539410016 · revised January 16, 2026
- [2]Health Canada (DPD) · 02493187 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.